Most Read

The deal has a total enterprise value of around $368m. Based in Cambridge, Horizon Discovery offers CRISPR and RNAi reagents, cell models, cell engineering and base editing solutions

Adakveo can be provided as an add-on therapy to hydroxyurea/hydroxycarbamide (HU/HC) or as monotherapy in patients for whom HU/HC is inappropriate or inadequate, said Novartis. Adakveo attaches to

Under the deal, Cheplapharm will purchase Atacand (candesartan cilexetil) and Atacand Plus (a fixed-dose combination of candesartan cilexetil and hydrochlorothiazide), which is marketed in around 70 countries across

Under the deal, Vedere shareholders have secured $150m upfront payment and also eligible to secure up to $130m in milestone payments. Vedere Bio has an advanced platform for

Under the deal, Bristol Myers Squibb and insitro will focus on the discovery and development of novel therapies to treat amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).

The US government will take the delivery of bamlanivimab vials after it achieves an emergency use authorisation (EUA) from the US Food and Drug Administration (FDA), said Eli

Aurinia has also secured funding for the VOCOVID study, which is a single-centre and investigator-initiated trial being carried out by Drs Aiko P.J. de Vries and Y.K. Onno

Gavi is the legal administrator of the COVAX Facility, which is part of COVAX, a global collaboration of governments, global health organisations, businesses and philanthropic organisations working to

The multicentre trial has been designed to assess the safety and efficacy of oral niclosamide formulation to treat patients with moderate Covid-19 disease. The study is said to